Each capsule contains Zidovudine USP 100
Each tablet contains Zidovudine USP 300
Zidovudine Oral Solution
Each 5 ml contains Zidovudine USP 50
Without a Prescription
Zidovudine as part of combination therapy is prescribed for the treatment of HIV infection when antiretroviral therapy is warranted.
Maternal-Fetal HIV Transmission: Zidovudine is prescribed for the prevention of maternal-fetal HIV transmission. The safety of zidovudine for the mother or foetus during the first trimester of pregnancy has not been assessed.
The recommended total oral daily dose of Zidovudine is 600 per day in divided doses in combination wth other antiretroviral agents and 500 mg (100 mg every 4 hours while awake) or 600 mg per day in divided doses for monotherapy.
Paediatrics: The recommended dose in children 3 months to 12 years of age is 180 /m 2 every 6 hours (720 mg/m 2 per day), not to exceed 200 mg every 6 hours.
Maternal-Fetal HIV Transmission: The recommended dosing regimen for administration to pregnant women (>14 weeks of pregnancy) and their neonates is:
Maternal dosing: 100 orally 5 times per day until the start of labour.
During labour and delivery, intravenous zidovudine should be administered at 2 /kg (total body weight) over 1 hour followed by a continuous intravenous infusion of 1 mg/kg/h (total body weight) until clamping of the umbilical cord.
Infant dosing: 2 /kg orally every 6 hours starting within 12 hours after birth and continuing through 6 weeks of age.
Infants unable to receive oral dosing may be administered zidovudine intravenously at 1.5 /kg, infused over 30 minutes, every 6 hours.
Haematologic toxicities appear to be related to pre-treatment bone marrow reserve and to dose and duration of therapy.
In patients who experience hematologic toxicity, reduction in hemoglobin may occur as early as 2 to 4 weeks, and neutropenia usually occurs after 6 to 8 weeks.
Dose adjustment: Significant anaemia (hemoglobin of <7.5 g/dL or reduction of >25% of baseline) and/or significant granulocytopenia (granulocyte count of <750 cells/mm 3 or reduction of >50% from baseline) may require a dose interruption until evidence of marrow recovery is observed.
For less severe anaemia or neutropenia, a reduction in daily dose may be adequate.
In patients who develop significant anaemia, dose modification does not necessarily eliminate the need for transfusion.
If marrow recovery occurs following dose modification, gradual increases in dose may be appropriate depending on hematologic indices and patient tolerance.
Impaired renal and hepatic function
In end-stage renal disease patients maintained on hemodialysis or peritoneal dialysis, recommended dosing is 100 every 6 to 8 hours.
There are insufficient data to recommend dosage adjustment of Zidovudine in patients with impaired hepatic function.
Zidovudine is contraindicated if you have any of the following conditions:
- Patients who exhibit potentially life-threatening allergic reactions to any of the components of the formulation;
- Bottle of 100 ml with syringe;
- Container of 100 capsules;
- Container of 60 tablets;
- Strip of 10 capsules;
- Strip of 10 tablets;